Skip to main content
SpringerLink
Log in

Complementary and Alternative Medicine and Lifestyle Changes and Prostate Cancer

  • Chapter
  • First Online:
Complementary & Alternative Medicine for Prostate and Urologic Health

  • 984 Accesses

Abstract

Pursuing high doses of antioxidants to prevent or assist in the treatment of prostate cancer may be simply providing impetus for more disease. It is important to “first do no harm” and think of heart-healthy regimens or CAM products that could simultaneously prevent or reduce the progression of cardiovascular disease and prostate cancer. This method allows researchers to focus on the forest and the tree(s). Virtually every single heart-healthy lifestyle change from smoking cessation, exercise, weight and waist loss, improving diet, and normalizing blood pressure, cholesterol, and glucose has now all been correlated with a lower risk of prostate cancer and even the potential to slow the progression of this disease with conventional treatment. The mantra for any man concerned or with prostate cancer should be “reduce your heart disease risk to as close to zero as possible” and at least a 2 for 1 benefit could be achieved. The SAM option, or statins, aspirin, and metformin, is a heart-healthy generic choice that appears to have the largest benefit-to-risk ratio for those that qualify and is of the lowest cost in the area of chemoprevention or as ancillary treatment to conventional medicine for prostate cancer. If a CAM can mimic any of these SAM or heart-healthy interventions, then it would be of enormous interest. For example, red yeast rice (RYR) extract has statin-like effects and may be an option for those that cannot tolerate prescription cholesterol-lowering agents. Otherwise, other CAM options have had serious issues when not following a heart-healthy = prostate-healthy scenario and when attempting to follow a more is better philosophy. Selenium in excess (200–800 micrograms) has toxicity issues and could accelerate PSA velocity in some patients with prostate cancer, and vitamin E in excess can significantly increase the risk of prostate cancer. Beta-carotene supplementation appears to increase the risk of lung cancer in former and current smokers in dosages as low as 15 mg. Fish oil supplements have not yet appeared to consistently provide benefits as expected in the area of cardiovascular health, but dietary fish consumption and plant omega-3 intake, such as flaxseed, may reduce the risk or progression of prostate cancer. Multivitamins in excess could increase the risk of aggressive prostate cancer, but a single low-dose children’s or adult Centrum Silver multivitamin appears to have no or a slight beneficial impact and may modestly reduce the risk of being diagnosed with cancer. Vitamin C has been given in IV form to advanced cancer patients with a hint of quality-of-life improvement but no clear clinical disease responses, and there are minor increasing oxalate issues. Vitamin D and calcium have important roles for bone health but have also been associated with prostate and other urologic issues in excess. Zinc has toxicity issues in higher doses (80 mg and higher) and may increase the risk of urologic problems including prostate cancer. Multiple other CAMs are discussed in this chapter including what should be utilized or not with androgen-deprivation therapy (ADT), but urology more than any other medical discipline has arguably proven that heart health is tantamount to prostate health and less is more.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin. 2013;63:11–30.

    PubMed  Google Scholar 

  2. Moyad MA. Zinc for prostate disease and other conditions: a little evidence, a lot of hype, and a significant potential problem. Urol Nurs. 2004;24:49–52.

    PubMed  Google Scholar 

  3. Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 2013;3:120144.

    PubMed  Google Scholar 

  4. Moyad MA. Promoting wellness for prostate cancer patients. 4th ed. Ann Arbor, MI: Spry; 2013.

    Google Scholar 

  5. Pinkhasov RM, Shteynshlyuger A, Hakimian P, Lindsay GK, Samadi DB, Shabsigh R. Are men shortchanged on health? Perspective on life expectancy, morbidity, and mortality in men and women in the United States. Int J Clin Pract. 2010;64:465–74.

    PubMed  CAS  Google Scholar 

  6. Moyad MA. Lifestyle changes to prevent BPH: heart healthy=prostate healthy. Urol Nurs. 2003;23: 439–41.

    PubMed  Google Scholar 

  7. Moyad MA. The optimal male health diet and dietary supplement program. Urol Clin North Am. 2012;39:89–107.

    PubMed  Google Scholar 

  8. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24.

    PubMed  CAS  Google Scholar 

  9. Scardino PT. The prevention of prostate cancer–the dilemma continues. N Engl J Med. 2003;349:297–9.

    PubMed  Google Scholar 

  10. Lebdai S, Bigot P, Azzouzi AR. High-grade prostate cancer and finasteride. BJU Int. 2010;105:456–9.

    PubMed  CAS  Google Scholar 

  11. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life–years analysis. Cancer. 2008;112:1058–65.

    PubMed  Google Scholar 

  12. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294:2996–3002.

    PubMed  CAS  Google Scholar 

  13. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;167:925–34.

    PubMed  Google Scholar 

  14. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202.

    PubMed  CAS  Google Scholar 

  15. Azzouni F, Mohler J. Role of 5-alpha-reductase inhibitors in prostate cancer prevention and treatment. Urology. 2012;79:1197–205.

    PubMed  Google Scholar 

  16. Walsh PC. Chemoprevention of prostate cancer. N Engl J Med. 2010;362:1237–8.

    PubMed  CAS  Google Scholar 

  17. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2009;18: 2807–13.

    PubMed  CAS  Google Scholar 

  18. Thomas II JA, Gerber L, Banez LL, Moreira DM, Rittmaster RS, Andriole GL, et al. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev. 2012;21:576–81.

    PubMed  CAS  Google Scholar 

  19. US Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General, GA: US Department of Health and Human Services, CDC. 2010. http://www.cdc.gov/tobacoo/data_statistics/sgr/2010/index.htm. Accessed 1 May 2013.

  20. Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults-United States, 2011. Morb Mortal Wkly Rep. 2012;61:889–94.

    Google Scholar 

  21. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100:693–701.

    PubMed  Google Scholar 

  22. Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control. 2009;20:1799–810.

    PubMed  Google Scholar 

  23. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548–55.

    PubMed  CAS  Google Scholar 

  24. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res. 2011;4:486–501.

    CAS  Google Scholar 

  25. Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EP, et al. Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res (Phila). 2011;4:544–51.

    Google Scholar 

  26. Discacciatl A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer–a dose response meta-analysis of prospective studies. Ann Oncol. 2012;23:1665–71.

    Google Scholar 

  27. Woodard G, Ahmed S, Podelski V, Hernandez-Boussard T, Presti Jr J, Morton JM. Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen. Br J Surg. 2012;99:693–8.

    PubMed  CAS  Google Scholar 

  28. Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 2010;101: 1073–9.

    PubMed  CAS  Google Scholar 

  29. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009;101:1272–9.

    PubMed  CAS  Google Scholar 

  30. Yun SJ, Min BD, Kang HW, Shin KS, Kim TH, Kim WT, et al. Elevated insulin and insulin resistance are associated with the advanced pathological stage of prostate cancer in Korean population. J Korean Med Sci. 2012;27:1079–84.

    PubMed  CAS  Google Scholar 

  31. Grossmann M, Wittert G. Androgens, diabetes and prostate cancer. Endocr Relat Cancer. 2012;19:F47–62.

    PubMed  CAS  Google Scholar 

  32. Centers for Disease Control and Prevention (CDC). Increasing prevalence of diagnosed diabetes-United States and Puerto Rico, 1995–2010. MMWR. 2012;61:918–21.

    Google Scholar 

  33. Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther. 2012;14 Suppl 1:S51–8.

    PubMed  CAS  Google Scholar 

  34. Grontved A, Rimm EB, Willett WC, Andersen LB, Hu FB. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Ann Intern Med. 2012;6:1–7.

    Google Scholar 

  35. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    PubMed  CAS  Google Scholar 

  36. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005; 142:611–9.

    PubMed  CAS  Google Scholar 

  37. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.

    Google Scholar 

  38. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379: 2243–51.

    PubMed  CAS  Google Scholar 

  39. CDC. Vital signs: prevalence, treatment, and control of hypertension-United States, 1992–2002 and 2005–2008. MMWR. 2011;60:103–8.

    Google Scholar 

  40. Rogers VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–209.

    Google Scholar 

  41. Neal B, McMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. Lancet. 2000;356: 1955–64.

    PubMed  CAS  Google Scholar 

  42. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 2012;344:e2697.

    PubMed  Google Scholar 

  43. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560–70.

    PubMed  Google Scholar 

  44. Loeb S, Gupta A, Losonczy L, Tosoian J, Walsh PC. Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk? Curr Opin Urol. 2013;23(1):2–4.

    PubMed  Google Scholar 

  45. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101 Suppl 3:17–21.

    PubMed  Google Scholar 

  46. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the Health Professionals Follow-up Study. J Clin Oncol. 2011;29:726–32.

    PubMed  Google Scholar 

  47. Oliveria SA, Lee IM. Is exercise beneficial in the prevention of prostate cancer? Sports Med. 1997;23:271–8.

    PubMed  CAS  Google Scholar 

  48. Torti DC, Matheson GO. Exercise and prostate cancer. Sports Med. 2004;34:363–9.

    PubMed  Google Scholar 

  49. Young-McCaughan S. Potential for prostate cancer prevention through physical activity. World J Urol. 2012;30:167–79.

    PubMed  Google Scholar 

  50. Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidemia: a cohort study. Lancet. 2013;381:394–9.

    PubMed  CAS  Google Scholar 

  51. Maio G, Saraeb S, Marchiori A. Physical function and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med. 2010;7:2201–8.

    PubMed  Google Scholar 

  52. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.

    PubMed  CAS  Google Scholar 

  53. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG, et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs. 2006;26:298–303.

    PubMed  Google Scholar 

  54. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Welchselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010;28:2653–9.

    PubMed  CAS  Google Scholar 

  55. Zaorsky NG, Buyyounouski MK, Li T, Horwitz EM. Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84:e13–7.

    PubMed  CAS  Google Scholar 

  56. Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010;116:1820–6.

    PubMed  CAS  Google Scholar 

  57. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013;63:709–16.

    PubMed  CAS  Google Scholar 

  58. Braun DP, Gupta D, Birdsall TC, Sumner M, Staren ED. Effect of naturopathic and nutritional supplement treatment on tumor response, control, and recurrence in patients with prostate cancer treated with radiation therapy. J Altern Complement Med. 2013;19:198–203.

    PubMed  Google Scholar 

  59. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst. 2005;97:481–8.

    PubMed  CAS  Google Scholar 

  60. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005;23:5805–13.

    PubMed  CAS  Google Scholar 

  61. Bairati I, Meyer F, Jobin E, Gelinas M, Fortin A, Nabid A, et al. Antioxidant vitamin supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer. 2006;119:2221–4.

    PubMed  CAS  Google Scholar 

  62. Meyer F, Bairati I, Fortin A, Gelinas M, Nabid A, Brochet F, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer. Int J Cancer. 2008;122:1679–83.

    PubMed  CAS  Google Scholar 

  63. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst. 2008;100:773–83.

    PubMed  CAS  Google Scholar 

  64. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012;11, CD006145.

    PubMed  Google Scholar 

  65. Mustian KM, Peppone L, Darling TV, Palesh O, Heckler CE, Morrow GR. A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. J Support Oncol. 2009;7:158–67.

    PubMed  Google Scholar 

  66. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27:344–51.

    PubMed  Google Scholar 

  67. Liu L, Glicksman AS, Coachman N, Kuten A. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;38:65–71.

    PubMed  CAS  Google Scholar 

  68. Pettersson A, Johansson B, Persson C, Berglund A, Turesson I. Effects of a dietary intervention on acute gastrointestinal side effects and other aspects of health-related quality of life: a randomized controlled trial in prostate cancer patients undergoing radiotherapy. Radiother Oncol. 2012;103:333–40.

    PubMed  Google Scholar 

  69. Lips IM, Kotte AN, van Gils CH, van Leerdam ME, van der Heide UA, van Vulpen M. Influence of antiflatulent dietary advice on intrafraction motion for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2011;81:e401–6.

    PubMed  Google Scholar 

  70. Lips IM, van Gils CH, Kotte AN, van Leerdam ME, Franken SP, van der Heide UA, et al. A double-blind placebo-controlled randomized clinical trial with magnesium oxide to reduce intrafraction prostate motion for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:653–60.

    PubMed  Google Scholar 

  71. Murphy J, Stacey D, Crook J, Thompson B, Panetta D. Testing control of radiation-induced diarrhea with a psyllium bulking agent: a pilot study. Can Oncol Nurs J. 2000;10:96–100.

    PubMed  CAS  Google Scholar 

  72. Muehlbauer PM, Thorpe D, Davis A, Drabot R, Rawlings BL, Kiker E. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. Clin J Oncol Nurs. 2009;13:336–41.

    PubMed  Google Scholar 

  73. The ATBC Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029–35.

    Google Scholar 

  74. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature. 1981;290:201–8.

    PubMed  CAS  Google Scholar 

  75. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150–5.

    PubMed  CAS  Google Scholar 

  76. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145–9.

    PubMed  CAS  Google Scholar 

  77. The Age-Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309:2005–15.

    Google Scholar 

  78. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51.

    PubMed  CAS  Google Scholar 

  79. Klein EA, Thompson Jr IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E cancer prevention trial (SELECT). JAMA. 2011;306:1549–56.

    PubMed  CAS  Google Scholar 

  80. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med. 2004;164:1552–6.

    PubMed  CAS  Google Scholar 

  81. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294:56–65.

    PubMed  CAS  Google Scholar 

  82. Miller III ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142:37–46.

    PubMed  CAS  Google Scholar 

  83. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293:1338–47.

    PubMed  Google Scholar 

  84. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301:52–62.

    PubMed  CAS  Google Scholar 

  85. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300:2123–33.

    PubMed  CAS  Google Scholar 

  86. Moyad MA. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology. 2002;59(4 Suppl 1):9–19.

    PubMed  Google Scholar 

  87. Lodge JK. Vitamin E, bioavailability in humans. J Plant Physiol. 2005;162:790–6.

    PubMed  CAS  Google Scholar 

  88. Duffield-Lillico AJ, Begg CB. Reflections on the landmark studies of beta-carotene supplementation. J Natl Cancer Inst. 2004;96:1729–30.

    PubMed  CAS  Google Scholar 

  89. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164:2335–42.

    PubMed  CAS  Google Scholar 

  90. Meyer F, Galan P, Douville P, Bairati I, Kegle P, Bertrais S, et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005;116:182–6.

    PubMed  CAS  Google Scholar 

  91. Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, et al. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst. 2005;97:396–9.

    PubMed  CAS  Google Scholar 

  92. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000;92:2018–23.

    PubMed  CAS  Google Scholar 

  93. Weinstein SJ, Peters U, Ahn J, Friesen MD, Riboli E, Hayes RB, et al. Serum alpha-tocopherol and gamma-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case-control study. PLoS One. 2012;7:e40204.

    PubMed  CAS  Google Scholar 

  94. Navas-Acien A, Bleys J, Guallar E. Selenium intake and cardiovascular risk: what is new? Curr Opin Lipidol. 2008;19:43–9.

    PubMed  CAS  Google Scholar 

  95. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs Jr GF, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst. 2003;95:1477–81.

    PubMed  CAS  Google Scholar 

  96. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147:217–23.

    PubMed  Google Scholar 

  97. Clark LC, Combs Jr GF, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA. 1996;276:1957–63.

    PubMed  CAS  Google Scholar 

  98. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.

    PubMed  CAS  Google Scholar 

  99. Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:641–8.

    PubMed  CAS  Google Scholar 

  100. Goossens ME, Buntinx F, Joniau S, Ackaert K, Ameye F, Billiet I, et al. Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. BMC Urol. 2012;12:8.

    PubMed  CAS  Google Scholar 

  101. Rothwell PM, Fowkes FG, Belch JK, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet. 2011;377:31–41.

    PubMed  CAS  Google Scholar 

  102. Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin N Am. 2011;38:243–59.

    Google Scholar 

  103. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46:2369–80.

    PubMed  CAS  Google Scholar 

  104. Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev. 2013;14:765–8.

    PubMed  Google Scholar 

  105. Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012;15:346–52.

    PubMed  CAS  Google Scholar 

  106. Moyad MA. Re: a prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. Eur Urol. 2012;61:623–4.

    PubMed  CAS  Google Scholar 

  107. Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109:1495–502.

    PubMed  CAS  Google Scholar 

  108. Murtola TJ, Visakorpi T, Lahtela J, Syvala H, Tammela TLJ. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol. 2008;5:376–87.

    PubMed  CAS  Google Scholar 

  109. Moyad MA. Heart health=urologic health and heart unhealthy=urologic unhealthy: rapid review of lifestyle changes and dietary supplements. Urol Clin N Am. 2011;38:359–67.

    Google Scholar 

  110. Colli JL, Amling CL. Exploring causes for declining prostate cancer mortality rates in the United States. Urol Oncol. 2008;26:627–33.

    PubMed  Google Scholar 

  111. Colli JL, Amling CL. High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. Urol Oncol. 2009;27:170–3.

    PubMed  CAS  Google Scholar 

  112. Statins and prostate cancer. http://www.clinicaltrials.gov. Accessed 10 May 2013.

  113. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–8.

    PubMed  Google Scholar 

  114. Metformin and cancer. http://www.clinicaltrials.gov. Accessed 10 May 2013.

  115. Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell. 2012;11:23–35.

    PubMed  CAS  Google Scholar 

  116. Moyad MA, Klotz LH. Statin clinical trial (REALITY) for prostate cancer: an over 15-year wait is finally over thanks to a dietary supplement. Urol Clin North Am. 2011;38:325–31.

    PubMed  Google Scholar 

  117. Wilt TJ, Macdonald R, Ishani A. B-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 1999;83:976–83.

    PubMed  CAS  Google Scholar 

  118. Wilt TJ, Ishani A, MacDonald R, Stark G, Mulrow CD, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;2, CD001043.

    PubMed  Google Scholar 

  119. Wilt T, MacDonald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;2, CD001042.

    PubMed  Google Scholar 

  120. Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract. 2009;3:323–7.

    PubMed  Google Scholar 

  121. Wilt T, Ishani A, MacDonald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;1, CD001044.

    PubMed  Google Scholar 

  122. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia (BPH). N Engl J Med. 2006;354: 557–66.

    PubMed  CAS  Google Scholar 

  123. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306:1344–51.

    PubMed  CAS  Google Scholar 

  124. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005;5:1–11.

    PubMed  Google Scholar 

  125. Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin 4th MT, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008;17:3577–87.

    PubMed  CAS  Google Scholar 

  126. Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food. 2008;11:207–14.

    PubMed  CAS  Google Scholar 

  127. Denmark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, Vollmer RT. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation on benign prostatic epithelium and prostate-specific antigen. Urology. 2004;63: 900–4.

    Google Scholar 

  128. Harper CR, Edwards MJ, DeFilipis AP, Jacobson TA. Flaxseed oil increases the plasma concentrations of cardioprotective (n-3) fatty acids in humans. J Nutr. 2006;136:83–7.

    PubMed  CAS  Google Scholar 

  129. DeLorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in the secondary prevention of coronary heart disease. Lancet. 1994;343: 1454–9.

    CAS  Google Scholar 

  130. Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: Part I. Urol Oncol. 2005;23:28–35.

    PubMed  CAS  Google Scholar 

  131. Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: Part II. Urol Oncol. 2005;23:36–48.

    PubMed  CAS  Google Scholar 

  132. Vrablik A, Prusikova M, Snejdrlova M, Zlatohlavek L. Omega-3 fatty acids and cardiovascular disease risk: do we understand the relationship. Physiol Res. 2009;58 Suppl 1:S19–26.

    PubMed  CAS  Google Scholar 

  133. Olson JH, Erie JC, Bakri SJ. Nutritional supplementation and age-related macular degeneration. Semin Ophthalmol. 2011;26:131–6.

    PubMed  Google Scholar 

  134. Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin Ophthalmol. 2011;22:279–82.

    PubMed  Google Scholar 

  135. Gopinath B, Flood VM, Rochtchina E, McMahon CM, Mitchell P. Consumption of omega-3 fatty acids and fish and risk of age-related hearing loss. Am J Clin Nutr. 2010;92:416–21.

    PubMed  CAS  Google Scholar 

  136. Neukam K, De Spirt S, Stahl W, Bejot M, Maurette JM, Tronnier H, et al. Supplementation of flaxseed oil diminishes skin sensitivity and improves skin barrier function and condition. Skin Pharmacol Physiol. 2011;24:67–74.

    PubMed  CAS  Google Scholar 

  137. Smith GI, Atherton P, Reeds DN, Mohammed BS, Rankin D, Rennie MJ, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr. 2011;93:402–12.

    PubMed  CAS  Google Scholar 

  138. Siener R, Jansen B, Watzer B, Hesse A. Effect of n-3 fatty acid supplementation on urinary risk factors for calcium oxalate stone formation. J Urol. 2011;185: 719–24.

    PubMed  CAS  Google Scholar 

  139. Klemens C, Berman D, Mozurkewich E. The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic diseases: a systematic review. BJOG. 2011;118:916–25.

    PubMed  CAS  Google Scholar 

  140. Freeman MP, Hibbein JR, Silver M, Hirschberg AM, Wang B, Yule AM, et al. Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. Menopause. 2011;18:279–84.

    PubMed  Google Scholar 

  141. Tajalizadekhoob Y, Sharifi F, Fakhrzadeh H, Mirarefin M, Ghaderpanahi M, Badamchizade Z, et al. The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci. 2011;261:539–49.

    PubMed  Google Scholar 

  142. Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011;83:1403–12.

    PubMed  Google Scholar 

  143. Brostow DP, Odegaard AO, Koh WP, Duval S, Gross MD, Yuan JM, et al. Omega-3 fatty acids and incident type 2 diabetes: the Singapore Chinese Health Study. Am J Clin Nutr. 2011;94:520–6.

    PubMed  CAS  Google Scholar 

  144. Meldrum DR, Gambone JC, Morris MA, Meldrum DA, Esposito K, Ignarro LJ. The link between erectile and cardiovascular health: the canary in the coal mine. Am J Cardiol. 2011;108:599–606.

    PubMed  Google Scholar 

  145. Showell MG, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev. 2011;1, CD007411.

    PubMed  Google Scholar 

  146. Risk and Prevention Study Collaborative Group. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800–8.

    Google Scholar 

  147. Mozaffarian D, Marchioli R, Macchia A, Silleta MG, Ferrazzi P, Gardner TJ, et al. Fish oil and postoperative atrial fibrillation: the Omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. JAMA. 2012;308: 2001–11.

    PubMed  CAS  Google Scholar 

  148. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024–33.

    PubMed  CAS  Google Scholar 

  149. Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr. 2010;92:1223–33.

    PubMed  CAS  Google Scholar 

  150. American Heart Association Web site. http://www.heart.org. Accessed 1 May 2013.

  151. Konings EJ. Water-soluble vitamins. J AOAC Int. 2006;89:285–8.

    PubMed  CAS  Google Scholar 

  152. Obican SG, Finnell RH, Mills JL, Shaw GM, Scialli AR. Folic acid in early pregnancy: a public health success story. FASEB J. 2010;24:4167–74.

    PubMed  CAS  Google Scholar 

  153. ZemLin AE, Essack Y, Rensburg M, Keller T, Brinkmann T. Stability of red blood cell folate in whole blood and haemolysate. Clin Lab. 2010;56:391–6.

    PubMed  CAS  Google Scholar 

  154. National Reference Laboratory. http://www.aruplab.com/guides/ug/tests/ugf.jsp. Accessed 5 Feb 2013.

  155. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131–7.

    Google Scholar 

  156. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832–5.

    PubMed  CAS  Google Scholar 

  157. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep. 1992;41(RR-14):1−7.

    Google Scholar 

  158. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology. 1995;6:219–26.

    PubMed  CAS  Google Scholar 

  159. LumLey J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev. 2001;3, CD001056.

    PubMed  Google Scholar 

  160. http://www.babylon.com/define/112/Latin-Dictionary.html. Accessed 6 Feb 2012.

  161. Zeisel SH. Importance of methyl donors during reproduction. Am J Clin Nutr. 2009;89:673S–7.

    PubMed  CAS  Google Scholar 

  162. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet C Semin Med Genet. 2004;125C:12–21.

    PubMed  Google Scholar 

  163. Institute of Medicine, Food and Nutrition Board. Folate. In: Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press; 2000. pp. 196−305.

    Google Scholar 

  164. Mason JB, Choi SW. Effects of alcohol on folate metabolism: implications for carcinogenesis. Alcohol. 2005;35:235–41.

    PubMed  CAS  Google Scholar 

  165. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28:1–10.

    PubMed  CAS  Google Scholar 

  166. Yerby MS. Management issues for women with epilepsy. Neural tube defects and folic acid supplementation. Neurology. 2003;61:S23–6.

    PubMed  CAS  Google Scholar 

  167. Pittschieler S, Brezinka C, Jahn B, Trinka E, Unterberger I, Dobesberger J, et al. Spontaneous abortions and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J Neurol. 2008;255(12): 1926–31.

    PubMed  CAS  Google Scholar 

  168. Wilson RD, Davies G, Desilets V, Rid GJ, Summers A, Wyatt P, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2003;25: 959–73.

    PubMed  Google Scholar 

  169. Tinker SC, Cogswell ME, Devine O, Berry RJ. Folic acid intake among U.S. women aged 15–44 years, National Health and Nutrition Examination Survey, 2003–2006. Am J Prev Med. 2010;38:534–42.

    PubMed  Google Scholar 

  170. Ferechide D, Radulescu D. Hyperhomocysteinemia in renal diseases. J Med Life. 2009;2:53–9.

    PubMed  Google Scholar 

  171. Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol. 2009;15:4653–8.

    PubMed  CAS  Google Scholar 

  172. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009;160:622–8.

    PubMed  CAS  Google Scholar 

  173. Chen CP. Syndromes, disorders and maternal risk factors associated with neural tube defects (I). Taiwan J Obstet Gynecol. 2008;47:1–9.

    PubMed  Google Scholar 

  174. Mojtabai R. Body mass index and serum folate in childbearing age women. Eur J Epidemiol. 2004;19:1029–36.

    PubMed  CAS  Google Scholar 

  175. Kim DB, Oh YS, Yoo KD, Lee JM, Park CS, Ihm SH, et al. Passive smoking in never-smokers is associated with increased plasma homocysteine levels. Int Heart J. 2010;51:183–7.

    PubMed  CAS  Google Scholar 

  176. Borrero S, Moore CG, Qin L, Schwarz EB, Akers A, Creinin MD, et al. Unintended pregnancy influences racial disparity in tubal sterilization rates. J Gen Intern Med. 2010;25:122–8.

    PubMed  Google Scholar 

  177. Rosenberg IH. A history of the isolation and identification of folic acid (folate). Ann Nutr Metab. 2012;61:231–5.

    PubMed  CAS  Google Scholar 

  178. Pietrzik K, Bailey L, Shane B. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010;49:535–48.

    PubMed  CAS  Google Scholar 

  179. U.S. Department of Agriculture’s Nutrient Database Web site. http://www.nal.usda.gov/fnic/cgi-bin/nut_search.pl. Accessed 17 May 2013.

  180. Roth C, Magnus P, Schjolberg S, Stoltenberg C, Suren P, McKeague IW, et al. Folic acid supplements in pregnancy and severe language delay in children. JAMA. 2011;306:1566–73.

    PubMed  CAS  Google Scholar 

  181. Suren P, Roth C, Bresnahan M, Haugen M, Horning M, Hirtz D, et al. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA. 2013;309:570–7.

    PubMed  CAS  Google Scholar 

  182. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med. 2010;170:1622–31.

    PubMed  CAS  Google Scholar 

  183. Cole BF, Baron JA, Sandler RS, Halle RW, Ahnen DJ, Bresaller RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297:2351–9.

    PubMed  CAS  Google Scholar 

  184. Figueriredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst. 2009;101:432–5.

    Google Scholar 

  185. Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:1632–42.

    PubMed  CAS  Google Scholar 

  186. Balley RL, Millis JL, Yetley EA, Gahche JJ, Pfeiffer CM, Dwyer JT, et al. Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally representative sample of adults aged > or =60 y in the United States. Am J Clin Nutr. 2010;92:383–9.

    Google Scholar 

  187. Wien TN, Pike E, Wisloff T, Staff A, Smeland S, Klemp M. Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open. 2012;2(1):e000653.

    PubMed  Google Scholar 

  188. Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomized trials: meta-analyses of data on 50,000 individuals. Lancet. 2013;381(9871): 1029–36.

    PubMed  CAS  Google Scholar 

  189. Qin X, Cui Y, Shen L, Sun N, Zhang Y, Li J, et al. Folic acid supplementation and cancer risk: a meta-analysis of randomized controlled trials. Int J Cancer. 2013. doi:10.1002/ijc.28038.

    Google Scholar 

  190. Bassett JK, Severi G, Hodge AM, Baglietto L, Hopper JL, English DR, et al. Dietary intake of B vitamins and methionine and prostate cancer incidence and mortality. Cancer Causes Control. 2012;23:855–63.

    PubMed  Google Scholar 

  191. Roswall N, Larsen SB, Frilis S, Outzen M, Olsen A, Christensen J, et al. Cancer Causes Control. 2013;24:1129–35.

    PubMed  Google Scholar 

  192. Wong WY, Merkus HM, Thomas CM, Menkveld R, Zielhuis GA, Steegers-Theunissen RP. Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertil Steril. 2002;77:491–8.

    PubMed  Google Scholar 

  193. Murphy LE, Mills JL, Molloy AM, Qian C, Carter TC, Strevens H, et al. Folate and vitamin B12 in idiopathic male infertility. Asian J Androl. 2011;13:856–61.

    PubMed  CAS  Google Scholar 

  194. Rock CL. Multivitamin-multimineral supplements: who uses them? Am J Clin Nutr. 2007;85(Suppl):277S–9.

    PubMed  CAS  Google Scholar 

  195. Barqawi A, Gamito E, O’Donnell C, Crawford ED. Herbal and vitamin supplement use in a prostate cancer screening population. Urology. 2004;63: 288–92.

    PubMed  Google Scholar 

  196. Zheng Selin J, Rautiainen S, Lindblad BE, Morgenstern R, Wolk A. High-dose supplements of vitamins C and E, low-dose multivitamins, and the risk of age-related cataract: a population-based prospective cohort study of men. Am J Epidemiol. 2013;177:548–55.

    PubMed  Google Scholar 

  197. Muntwyler J, Hennekens CH, Manson JE, Buring JE, Gaziano M. Vitamin supplement use in a low-risk population of US male physicians and subsequent cardiovascular mortality. Arch Intern Med. 2002;162:1472–6.

    PubMed  Google Scholar 

  198. Giovannucci E, Chan AT. Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol. 2010;28:4081–5.

    PubMed  CAS  Google Scholar 

  199. Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst. 2007;99:754–64.

    PubMed  CAS  Google Scholar 

  200. Stevens VL, McCullough ML, Diver WR, Rodriguez C, Jacobs EJ, Thun MJ, et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control. 2005;16:643–50.

    PubMed  Google Scholar 

  201. Neuhouser ML, Barnett MJ, Kristal AR, Ambrosone CB, King IB, Thornquist M, et al. Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev. 2009;18:2202–6.

    PubMed  CAS  Google Scholar 

  202. Larsson SC, Akesson A, Bergkvist L, Wolk A. Multivitamin use and breast cancer incidence in a prospective cohort of Swedish women. Am J Clin Nutr. 2010;91:1268–72.

    PubMed  CAS  Google Scholar 

  203. Berube S, Diorio C, Brisson J. Multivitamin-multimineral supplement use and mammographic breast density. Am J Clin Nutr. 2008;87:1400–4.

    PubMed  CAS  Google Scholar 

  204. Rosen J, Gardiner P, Saper RB, Fillppelli A, White LF, Pearce EN, et al. Complementary and alternative medicine use among patients with thyroid cancer. Thyroid. 2013. Epub ahead of print.

    Google Scholar 

  205. Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, et al. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2010;28:4354–63.

    PubMed  Google Scholar 

  206. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians’ Health Study II-a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000;10:125–34.

    PubMed  CAS  Google Scholar 

  207. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2012;308:1871–80.

    PubMed  CAS  Google Scholar 

  208. Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2012;308:1751–60.

    PubMed  CAS  Google Scholar 

  209. van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, et al. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin. 2007;23: 2063–70.

    PubMed  Google Scholar 

  210. Thompson IM, Tangen CM, Klein EA, Lippman SM. Phase III prostate cancer prevention trials: are the costs justified? J Clin Oncol. 2005;23:8161–4.

    PubMed  Google Scholar 

  211. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol. 2001;166:1311–5.

    PubMed  CAS  Google Scholar 

  212. Nijjar PS, Burke FM, Bloesch A, Rader DJ. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol. 2010;4:248–58.

    PubMed  Google Scholar 

  213. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–9.

    PubMed  Google Scholar 

  214. Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol. 2010;105:664–6.

    PubMed  CAS  Google Scholar 

  215. Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, et al. Tolerability of red yeast rice (2400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105:198–204.

    PubMed  CAS  Google Scholar 

  216. Sikka P, Kapoor S, Bindra VK, Sharma M, Vishwakarma P, Saxena KK. Statin intolerance: now a solved problem. J Postgrad Med. 2011;57:321–8.

    PubMed  CAS  Google Scholar 

  217. Red yeast rice. Med Lett Drugs Ther. 2009;51:71–2.

    Google Scholar 

  218. Lin Y-L, Wang T-H, Lee M-H, Su N-W. Biologically active components and nutraceuticals in the Monascus-fermented rice: a review. Appl Microbiol Biotechnol. 2008;77:965–73.

    PubMed  CAS  Google Scholar 

  219. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo). 1979;32:852–4.

    CAS  Google Scholar 

  220. Landers P. Stalking cholesterol. How one scientist intrigued by molds found first statin. Feat of Japan’s Dr. Endo led to heart-care revolution but brought him nothing. Nature as a drug laboratory. Wall Street Journal, January 9, 2006, pp. A1, A8.

    Google Scholar 

  221. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.

    PubMed  Google Scholar 

  222. Lu Z, Kou W, Du B, et al. Effects of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–93.

    PubMed  Google Scholar 

  223. China Coronary Secondary Prevention Study Group. China coronary secondary prevention study (CCSPS)-Lipid regulating therapy with xuezhikang for secondary prevention of coronary heart disease. Chin J Cardiol (Chin). 2005;33:109–15.

    Google Scholar 

  224. Ye P, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, et al. Effects of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from China coronary secondary prevention study. J Am Geriatr Soc. 2007;55:1015–22.

    PubMed  Google Scholar 

  225. Hong MY, Seeram NP, Zhang Y, Heber D. Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. J Med Food. 2008;11:657–66.

    PubMed  CAS  Google Scholar 

  226. Hong MY, Henning S, Moro A, Seeram NP, Zhang Y, Heber D. Chinese red yeast rice inhibition of prostate tumor growth in SCID mice. Cancer Prev Res (Phila). 2011;4:608–15.

    CAS  Google Scholar 

  227. Hong MY, Seeram NP, Zhang Y, Heber D. Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem. 2008;19:448–58.

    PubMed  CAS  Google Scholar 

  228. Ma KY, Zhang ZS, Zhao SX, Chang Q, Wong YM, Yeung SY, et al. Red yeast increases excretion of bile acids in hamsters. Biomed Environ Sci. 2009;22:269–77.

    PubMed  CAS  Google Scholar 

  229. Li JJ, Hu SS, Fang CH, Hui RT, Miao LF, Yang YJ, et al. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta. 2005;352:217–24.

    PubMed  CAS  Google Scholar 

  230. Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation. 2004;110:915–20.

    PubMed  Google Scholar 

  231. Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem. 2003;49:1347–52.

    PubMed  Google Scholar 

  232. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005;95:961–2.

    PubMed  CAS  Google Scholar 

  233. Solomon KR, Pelton K, Boucher K, Joo J, Tully C, Zurakowski D, et al. Ezetimibe is an inhibitor if tumor angiogenesis. Am J Pathol. 2009;174:1017–26.

    PubMed  CAS  Google Scholar 

  234. Moyad MA, Merrick GS. Statins and cholesterol lowering after a cancer diagnosis: why not? Urol Oncol. 2005;23:49–55.

    PubMed  Google Scholar 

  235. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol. 2006;7:355–62.

    PubMed  Google Scholar 

  236. Gotto Jr AM, Whitney E, Stein EA, Shapiro SR, Clearfield M, Weis S, et al. Relation between baseline and on treatment lipid parameters and first major acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–84.

    PubMed  CAS  Google Scholar 

  237. Nakamura H, for the MEGA Study Group. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. Atheroscler Suppl. 2007;8:13–7.

    PubMed  CAS  Google Scholar 

  238. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware. Arch Intern Med. 2010;170:1722–7.

    PubMed  CAS  Google Scholar 

  239. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7:133–9.

    PubMed  CAS  Google Scholar 

  240. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995;52:1639–45.

    PubMed  CAS  Google Scholar 

  241. Schacter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–25.

    Google Scholar 

  242. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci. 1999;65:1329–37.

    PubMed  CAS  Google Scholar 

  243. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, et al. Phase I clinical trial of I.V. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19:1969–74.

    PubMed  CAS  Google Scholar 

  244. Robitalle L, Mamer OA, Miller Jr WH, Levine M, Assouline S, Melnychuk D, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism. 2009;58:263–9.

    Google Scholar 

  245. Thomas LD, Elinder CG, Tiselius HG, Wolk A, Akesson A. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med. 2013;173:386–8.

    PubMed  Google Scholar 

  246. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res. 2009;29:809–15.

    PubMed  CAS  Google Scholar 

  247. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010;21:1297–303.

    PubMed  Google Scholar 

  248. Michaelsson K, Baron JA, Snellman G, Gedeborg R, Byberg L, Sundstrom J, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92:841–8.

    PubMed  CAS  Google Scholar 

  249. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women. JAMA. 2010;303:1815–22.

    PubMed  CAS  Google Scholar 

  250. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28.

    PubMed  CAS  Google Scholar 

  251. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr. 2008;87(Suppl):1087S–91.

    PubMed  CAS  Google Scholar 

  252. Isenor JE, Ensom MH. Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk. Pharmacotherapy. 2010;30: 254–64.

    PubMed  CAS  Google Scholar 

  253. Kopes-Kerr C. Should family physicians routinely screen for vitamin d deficiency? No: screening is unnecessary, and routine supplementation makes more sense. Am Fam Physician. 2013;87(8):Online.

    Google Scholar 

  254. Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effects of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308:1333–9.

    PubMed  CAS  Google Scholar 

  255. Moyad MA. Dr Moyad’s no bogus science health advice. Ann Arbor, MI: Ann Arbor Media Group; 2009.

    Google Scholar 

  256. Wolpowitz D, Gilchrest BA. The vitamin D questions: how much do you need and how should you get it? J Am Acad Dermatol. 2006;54:301–17.

    PubMed  Google Scholar 

  257. Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451–9.

    PubMed  CAS  Google Scholar 

  258. Aasheim ET, Hofso D, Hjelmesaeth J, Birkeland KI, Bohmer T. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr. 2008;87:362–9.

    PubMed  CAS  Google Scholar 

  259. Perez-Castrillon JL, Abad L, Vega G, Sanz-Cantalapiedra A, Garcia-Porrero M, Pinacho F, et al. Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Eur Rev Med Pharmacol Sci. 2008;12:83–8.

    PubMed  CAS  Google Scholar 

  260. Chen TC, Chimeh F, Lu Z, Mathieu J, Person KS, Zhang A, et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys. 2007;460:213–7.

    PubMed  CAS  Google Scholar 

  261. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and benefits. JAMA. 2006;296:1885–99.

    PubMed  CAS  Google Scholar 

  262. Levis S, Gomez A, Jimenez C, Veras L, Ma F, Lai S, et al. Vitamin D deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab. 2005;90:1557–62.

    PubMed  CAS  Google Scholar 

  263. Jacobs ET, Alberts DS, Foote JA, Green SB, Hollis BW, Yu Z, et al. Vitamin D insufficiency in southern Arizona. Am J Clin Nutr. 2008;87:608–13.

    PubMed  CAS  Google Scholar 

  264. Chel V, Wijnhoven HAH, Smit JH, Ooms M, Lips P. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int. 2008;19:663–71.

    PubMed  CAS  Google Scholar 

  265. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006;84:694–7.

    PubMed  CAS  Google Scholar 

  266. Welch TR, Bergstrom WH, Tsang RC. Vitamin D-deficient rickets: the reemergence of a once-conquered disease. J Pediatr. 2000;137:143–5.

    PubMed  CAS  Google Scholar 

  267. Rajakumar K, Thomas SB. Reemerging nutritional rickets: a historical perspective. Arch Pediatr Adolesc Med. 2005;159:335–41.

    PubMed  Google Scholar 

  268. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. 2010. http://www.iom.edu/vitamind. Accessed 1 May 2013.

  269. Slomski A. IOM endorses vitamin D, calcium only for bone health, dispels deficiency claims. JAMA. 2011;305:453–4.

    PubMed  CAS  Google Scholar 

  270. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med. 2002;112:659–62.

    PubMed  CAS  Google Scholar 

  271. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998;8:222–30.

    PubMed  CAS  Google Scholar 

  272. Harris SS, Dawson-Hughes B, Perrone GA. Plasma 25-hydroxyvitamin D responses of younger and older men to three weeks of supplementation with 1800 IU/day of vitamin D. J Am Coll Nutr. 1999;18:470–4.

    PubMed  CAS  Google Scholar 

  273. Harris SS, Dawson-Hughes B. Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3. J Am Coll Nutr. 2002;21:357–62.

    PubMed  CAS  Google Scholar 

  274. Heaney RP. Vitamin D: criteria for safety and efficacy. Nutr Rev. 2008;66(10 Suppl 2):S178–81.

    PubMed  Google Scholar 

  275. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2004;108:104–8.

    PubMed  CAS  Google Scholar 

  276. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100:796–804.

    PubMed  CAS  Google Scholar 

  277. Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjonneland A, et al. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Epidemiol. 2009;169:1223–32.

    PubMed  Google Scholar 

  278. Meyer HE, Robsahm TE, Bjorge T, Brustad M, Blomhoff R. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr. 2013;97:147–54.

    PubMed  CAS  Google Scholar 

  279. Brandstedt J, Almquist M, Manjer J, Maim J. Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control. 2012;23:1377–85.

    PubMed  Google Scholar 

  280. Barnett CM, Beer TM. Prostate cancer and vitamin D: what does the evidence really suggest? Urol Clin N Am. 2011;38:333–42.

    Google Scholar 

  281. Vieth R. Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol. 2004;89–90:575–9.

    PubMed  Google Scholar 

  282. Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporos Int. 2002;13:187–94.

    PubMed  CAS  Google Scholar 

  283. Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacia bone involvement. Calcif Tissue Int. 2000;66: 419–24.

    PubMed  CAS  Google Scholar 

  284. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004;291:1999–2006.

    PubMed  CAS  Google Scholar 

  285. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38:2045–52.

    PubMed  Google Scholar 

  286. Kukuijan S, Nowson CA, Sanders K, Daly RM. Effects of resistance exercise and fortified milk on skeletal muscle mass, muscle size, and functional performance in middle-aged and older men: an 18-mo randomized trial. J Appl Physiol. 2009;107: 1864–73.

    Google Scholar 

  287. Kukuijan S, Nowson CA, Sanders KM, Nicholson GC, Seibel MJ, Salmon J, et al. Independent and combined effects of calcium-vitamin D3 and exercise on bone structure and strength in older men: an 18-month factorial design randomized trial. J Clin Endocrinol Metab. 2011;96:955–63.

    Google Scholar 

  288. Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart. 2012;98:920–5.

    PubMed  CAS  Google Scholar 

  289. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev. 2003;12:597–603.

    PubMed  CAS  Google Scholar 

  290. Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:203–10.

    PubMed  CAS  Google Scholar 

  291. Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, et al. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev. 2005;14:586–9.

    PubMed  CAS  Google Scholar 

  292. Kristal AR, Chi C, Tangen CM, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106:320–8.

    PubMed  Google Scholar 

  293. Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 2007;99:812–6.

    PubMed  CAS  Google Scholar 

  294. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104:800–5.

    PubMed  CAS  Google Scholar 

  295. Panju AH, Breunis H, Cheung AM, Leach M, Fleshner N, Warde P, et al. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int. 2009;103:753–7.

    PubMed  CAS  Google Scholar 

  296. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med. 1999;340: 101–7.

    PubMed  CAS  Google Scholar 

  297. Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomized intervention trial. European Cancer Prevention Organization Study Group. Lancet. 2005;356:1300–6.

    Google Scholar 

  298. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346:77–84.

    PubMed  CAS  Google Scholar 

  299. Saper RB, Rash R. Zinc: an essential micronutrient. Am Fam Physician. 2009;79:768.

    PubMed  Google Scholar 

  300. Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL. Zinc supplement use and risk of prostate cancer. J Am Cancer Inst. 2002;95:1004–7.

    Google Scholar 

  301. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report Number 8. Arch Ophthalmol. 2001;119:1417–36.

    Google Scholar 

  302. Johnson AR, Munoz A, Gottlieb JL, Jarrard DF. High dose zinc increases hospital admissions due to genitourinary complications. J Urol. 2007;177:639–43.

    PubMed  CAS  Google Scholar 

  303. Sanchez C, Lopez-Jurado M, Planells E, Llopis J, Aranda P. Assessment of iron and zinc intake and related biochemical parameters in an adult Mediterranean population from southern Spain: influence of lifestyle factors. J Nutr Biochem. 2009;20:125–31.

    PubMed  CAS  Google Scholar 

  304. Fashner J, Ericson K, Werner S. Treatment of the common cold in children and adults. Am Fam Physician. 2012;86:153–9.

    PubMed  Google Scholar 

  305. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006;12(13):4018–26.

    PubMed  CAS  Google Scholar 

  306. Bell C, Hawthrone S. Ellagic acid, pomegranate and prostate cancer—a mini review. J Pharm Pharmacol. 2008;60:139–44.

    PubMed  CAS  Google Scholar 

  307. Nelson JB, Sleep DJ, Isaacson JD, Carducci MA. Limitation of prostate-specific antigen doubling time as a predictor of outcome in hormone-naïve prostate cancer. J Clin Oncol. 2006;25(18S):233S-abstract 4566.

    Google Scholar 

  308. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765–71.

    PubMed  Google Scholar 

  309. Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013;16:50–5.

    PubMed  CAS  Google Scholar 

  310. Leitzmann MF, Platz EA, Stampfer MJ, Willett WC, Giovannucci E. Ejaculation frequency and subsequent risk of prostate cancer. JAMA. 2004;291: 1578–86.

    PubMed  CAS  Google Scholar 

  311. Zhou J, Smith S, Giovannucci E, Michaud DS. Reexamination of total fluid intake and bladder cancer in the Health Professionals Follow-up Study Cohort. Am J Epidemiol. 2012;175:696–705.

    PubMed  Google Scholar 

  312. Sharifi N, Gulley JL, Dahut WL. An update on androgen therapy for prostate cancer. Endocr Relat Cancer. 2010;17:R305–15.

    PubMed  CAS  Google Scholar 

  313. Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16:1851–63.

    PubMed  CAS  Google Scholar 

  314. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Mateev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.

    PubMed  Google Scholar 

  315. Adler RA. Management of osteoporosis in men on androgen deprivation therapy. Maturitas. 2011;68: 143–7.

    PubMed  CAS  Google Scholar 

  316. Beebe-Dimmer J, Morgenstern H, Cetin K, Yee C, Bartoces M, Shahinian V, et al. Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States. Ann Epidemiol. 2011;21:156–63.

    PubMed  Google Scholar 

  317. Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care. 2010;4:147–52.

    PubMed  Google Scholar 

  318. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009;24 Suppl 2:S389–94.

    PubMed  Google Scholar 

  319. Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol. 2005;23:56–64.

    PubMed  Google Scholar 

  320. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79:933–41.

    PubMed  CAS  Google Scholar 

  321. Malone S, Perry G, Segal R, Dahrouge S, Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int. 2005;96:514–20.

    PubMed  CAS  Google Scholar 

  322. Nilsson-Ehle H, Jagenburg R, Landahl S, Svanborg A. Blood hemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol. 2000;65:297–305.

    PubMed  CAS  Google Scholar 

  323. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med. 2006;166:1380–8.

    PubMed  CAS  Google Scholar 

  324. Hara N, Nishiyama T, Takizawa I, Saito T, Kitamura Y, Takahashi K. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis. Urology. 2010;75:1441–5.

    PubMed  Google Scholar 

  325. Diamond TH, Higan CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892–9.

    PubMed  Google Scholar 

  326. Wang W, Yussa T, Tsuchiya N, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer. 2008;15:943–52.

    PubMed  CAS  Google Scholar 

  327. Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, et al. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology. 2010;75:1131–7.

    PubMed  Google Scholar 

  328. Iso H. Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb. 2011;18:83–8.

    PubMed  Google Scholar 

  329. Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology. 2007;70:122–6.

    PubMed  Google Scholar 

  330. Planas J, Morote J, Orsola A, Salvador C, Trilla E, Cecchini L, et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int. 2007;99:812–5.

    PubMed  CAS  Google Scholar 

  331. Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother. 2006;40:2107–14.

    PubMed  Google Scholar 

  332. Yee EF, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med. 2007;22:1305–10.

    PubMed  Google Scholar 

  333. Smith MR, Egerdie B, Harnandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55.

    PubMed  CAS  Google Scholar 

  334. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28:340–7.

    PubMed  CAS  Google Scholar 

  335. Borsheim E, Bui QU, Tissier S, Kobayashi H, Ferrando AA, Wolfe RR, et al. Effect of amino acid supplementation on muscle mass, strength and physical function in the elderly. Clin Nutr. 2008;27:189–95.

    PubMed  CAS  Google Scholar 

  336. Scognamiglio R, Avogaro A, Negut C, Piccolotto R, de Kreutzenberg SV, Tiengo A. The effects of oral amino acid intake on ambulatory capacity in elderly subjects. Aging Clin Exp Res. 2004;16:443–7.

    PubMed  CAS  Google Scholar 

  337. Dillon EL, Sheffield-Moore M, Paddon-Jones D, Gilkison C, Sanford AP, Casperson SL, et al. Amino acid supplementation increases lean body mass, basal muscle protein synthesis, and insulin-like growth factor-I expression in older women. J Clin Endocrinol Metab. 2009;94:1630–7.

    PubMed  CAS  Google Scholar 

  338. Pennings B, Boirie Y, Senden JM, Gijsen AP, Kuipers H, van Loon LJ. Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men. Am J Clin Nutr. 2011;93:997–1005.

    PubMed  CAS  Google Scholar 

  339. Schmitz KH, Ahmed RL, Troxel AB, Cheville A, Lewis-Grant L, Smith R, et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA. 2010;304: 2699–705.

    PubMed  CAS  Google Scholar 

  340. Nair KS, Rizza RA, O’Brien P, Dhatariya K, Short KR, Nehra A, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647–59.

    PubMed  CAS  Google Scholar 

  341. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288:2282–92.

    PubMed  CAS  Google Scholar 

  342. Taaffe DR, Pruitt L, Reim J, Hintz RL, Butterfield G, Hoffman AR, et al. Effect of recombinant growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab. 1994;79:1361–6.

    PubMed  CAS  Google Scholar 

  343. Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833–40.

    PubMed  Google Scholar 

  344. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306:2359–66.

    PubMed  CAS  Google Scholar 

  345. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol. 2006;176:520–5.

    PubMed  Google Scholar 

  346. Fetterman Jr JW, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm. 2009;66:1169–79.

    PubMed  CAS  Google Scholar 

  347. Taouis M, Dagou C, Ster C, Durand G, Pinault M, Delarue J. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am J Physiol Endocrinol Metab. 2002;282: E664–71.

    PubMed  CAS  Google Scholar 

  348. Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem. 2006;17:1–13.

    PubMed  CAS  Google Scholar 

  349. Fedor D, Kelley DS. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care. 2009;12:138–46.

    PubMed  CAS  Google Scholar 

  350. Carpenter YA, Portois L, Malaisse WJ. N-3 fatty acids and the metabolic syndrome. Am J Clin Nutr. 2006;83(Suppl):1499S–504.

    Google Scholar 

  351. Rudkowska I. Fish oil for cardiovascular disease: impact on diabetes. Maturitas. 2010;67:25–8.

    PubMed  CAS  Google Scholar 

  352. Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007;100:1060–5.

    PubMed  Google Scholar 

  353. Kris-Etherton PM, Harris WS, Appel LJ, AHA Nutrition Committee, American Heart Association. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151–2.

    PubMed  CAS  Google Scholar 

  354. Braith RW, Stewart KJ. Resistance exercise training: its role in the prevention of cardiovascular disease. Circulation. 2006;113:2642–50.

    PubMed  Google Scholar 

  355. Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010;18:179–87.

    PubMed  Google Scholar 

  356. Cormie P, Newton RU, Taaffe DR, Spry N, Joseph D, Akhill Hamid M, et al. Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial. Prostate Cancer Prostatic Dis. 2013;16:170–5.

    PubMed  CAS  Google Scholar 

  357. Kontos M, Agbaje OF, Rymer J, Fentiman IS. What can be done about hot flushes after treatment for breast cancer? Climacteric. 2010;13:4–21.

    PubMed  CAS  Google Scholar 

  358. Moyad MA. Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research. Urology. 2002;59(4 Suppl 1):34–40.

    PubMed  Google Scholar 

  359. Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomized trial. Lancet. 2010;11: 147–54.

    CAS  Google Scholar 

  360. Langenstroer P, Kramer B, Cutting B, Amling C, Poultan T, Lance R, et al. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol. 2005;174: 642–5.

    PubMed  CAS  Google Scholar 

  361. Lucas M, Asselin G, Merette C, Poulin MJ, Dodin S. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause. 2009;16:357–66.

    PubMed  Google Scholar 

  362. Freeman MP. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry. 2009;70 Suppl 5:7–11.

    PubMed  CAS  Google Scholar 

  363. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2009;28:525–42.

    PubMed  CAS  Google Scholar 

  364. Ryan JL, Heckler CE, Roscoe JA, Dakhll SR, Kirshner J, Flynn PJ, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2012;20:1479–89.

    PubMed  Google Scholar 

  365. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279.

    PubMed  Google Scholar 

  366. Koh EH, Lee WJ, Lee SA, Kim EH, Cho EH, Jeong E, et al. Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med. 2011;124:85e1–8.

    Google Scholar 

  367. Marshall JR, Tangen CM, Sakr WA, Wood Jr DP, Berry DL, Klein EA, et al. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res. 2011;4:1761–9.

    CAS  Google Scholar 

  368. Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, et al. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy and selenium. J Clin Oncol. 2011;29: 2386–90.

    PubMed  CAS  Google Scholar 

  369. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate. 2013;73:328–35.

    PubMed  CAS  Google Scholar 

  370. Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila). 2010;3:1035–43.

    CAS  Google Scholar 

  371. Bauer CM, Ishak MB, Johnson EK, Beebe-Dimmer JL, Cooney KA. Prevalence and correlates of vitamin and supplement usage among men with a family history of prostate cancer. Integr Cancer Ther. 2012;11:83–9.

    PubMed  CAS  Google Scholar 

  372. McCullough MK, Patel AV, Kushi LH, Patel R, Willet WC, Doyle C, et al. Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality. Cancer Epidemiol Biomarkers Prev. 2011;20:1089–97.

    PubMed  Google Scholar 

  373. Thomas RJ, Holm M, Williams M, Bowman E, Bellamy P, Andreyev J, et al. Lifestyle factors correlate with the risk of late pelvic symptoms after prostatic radiotherapy. Clin Oncol (R Coll Radiol). 2013;25:246–51.

    CAS  Google Scholar 

  374. Park SW, Kim TN, Nam JK, Ha HK, Shin DG, Lee W, et al. Recovery of overall exercise ability, quality of life, and continence after 12-week combined exercise intervention in elderly patients who underwent radical prostatectomy: a randomized controlled trial. Urology. 2012;80:299–305.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA

    Mark A. Moyad M.D., M.P.H.

Authors
  1. Mark A. Moyad M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Moyad, M.A. (2014). Complementary and Alternative Medicine and Lifestyle Changes and Prostate Cancer. In: Complementary & Alternative Medicine for Prostate and Urologic Health. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8492-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8492-9_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8491-2

  • Online ISBN: 978-1-4614-8492-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation